Immune checkpoint inhibitors combined with tyrosine kinase inhibitors is the treatment option of previously treated advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration.

ABSTRACT:

SUBMITTER: Yang X 

PROVIDER: S-EPMC9641038 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature